DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $89,224,201 | +2.0% | 359,630 | -1.4% | 0.70% | +7.3% |
| Q2 2023 | $87,504,240 | -6.6% | 364,601 | -1.9% | 0.66% | -10.8% |
| Q1 2023 | $93,658,819 | -5.3% | 371,603 | -0.3% | 0.73% | -8.7% |
| Q4 2022 | $98,939,550 | +1.6% | 372,766 | -1.1% | 0.80% | -5.0% |
| Q3 2022 | $97,369,000 | -0.9% | 376,975 | -2.7% | 0.85% | +5.8% |
| Q2 2022 | $98,241,000 | -13.2% | 387,509 | +0.4% | 0.80% | +3.1% |
| Q1 2022 | $113,238,000 | -10.1% | 386,043 | +0.8% | 0.78% | -5.8% |
| Q4 2021 | $125,955,000 | +8.2% | 382,831 | +0.1% | 0.82% | +0.1% |
| Q3 2021 | $116,384,000 | +12.2% | 382,288 | -1.1% | 0.82% | +11.8% |
| Q2 2021 | $103,704,000 | +20.6% | 386,433 | +1.2% | 0.74% | +12.5% |
| Q1 2021 | $85,970,000 | +0.3% | 381,958 | -1.0% | 0.65% | -5.6% |
| Q4 2020 | $85,742,000 | +3.0% | 385,980 | -0.1% | 0.69% | -7.8% |
| Q3 2020 | $83,215,000 | +21.4% | 386,459 | -0.3% | 0.75% | +12.6% |
| Q2 2020 | $68,528,000 | +31.5% | 387,537 | +2.9% | 0.67% | +5.9% |
| Q1 2020 | $52,111,000 | -10.6% | 376,504 | -0.9% | 0.63% | +13.7% |
| Q4 2019 | $58,314,000 | +5.7% | 379,945 | -0.6% | 0.56% | -1.9% |
| Q3 2019 | $55,190,000 | -12.3% | 382,118 | -13.2% | 0.57% | -19.8% |
| Q2 2019 | $62,951,000 | +8.2% | 440,464 | -0.1% | 0.71% | +2.5% |
| Q1 2019 | $58,181,000 | +30.7% | 440,703 | +2.1% | 0.69% | +21.5% |
| Q4 2018 | $44,522,000 | -3.6% | 431,748 | +1.6% | 0.57% | +3.1% |
| Q3 2018 | $46,192,000 | +10.4% | 425,099 | +0.3% | 0.55% | +3.4% |
| Q2 2018 | $41,835,000 | -49.5% | 423,938 | -49.9% | 0.53% | -2.7% |
| Q1 2018 | $82,842,000 | +107.4% | 846,104 | +96.6% | 0.55% | +5.2% |
| Q4 2017 | $39,941,000 | +9.1% | 430,308 | +0.8% | 0.52% | +4.4% |
| Q3 2017 | $36,620,000 | +6.6% | 426,902 | +4.9% | 0.50% | +3.3% |
| Q2 2017 | $34,347,000 | -0.8% | 406,996 | +0.5% | 0.48% | -2.4% |
| Q1 2017 | $34,625,000 | +10.2% | 404,829 | +0.3% | 0.49% | +5.3% |
| Q4 2016 | $31,409,000 | +0.0% | 403,508 | +0.7% | 0.47% | -4.1% |
| Q3 2016 | $31,407,000 | -23.2% | 400,644 | -1.1% | 0.49% | -24.4% |
| Q2 2016 | $40,909,000 | +5.7% | 405,045 | -0.7% | 0.65% | +0.8% |
| Q1 2016 | $38,701,000 | +4.4% | 407,979 | +2.3% | 0.64% | +3.5% |
| Q4 2015 | $37,053,000 | +9.3% | 398,943 | +0.3% | 0.62% | +6.3% |
| Q3 2015 | $33,888,000 | +1.0% | 397,699 | +1.5% | 0.58% | +11.0% |
| Q2 2015 | $33,538,000 | +2.4% | 391,853 | +1.5% | 0.52% | +3.1% |
| Q1 2015 | $32,765,000 | -0.7% | 385,924 | +0.2% | 0.51% | -2.5% |
| Q4 2014 | $33,011,000 | +13.9% | 385,154 | +0.9% | 0.52% | +9.2% |
| Q3 2014 | $28,993,000 | -1.8% | 381,587 | +1.7% | 0.48% | -1.0% |
| Q2 2014 | $29,539,000 | +6.4% | 375,204 | +1.4% | 0.48% | +2.3% |
| Q1 2014 | $27,753,000 | -2.3% | 370,046 | +0.6% | 0.47% | -4.1% |
| Q4 2013 | $28,394,000 | +10.3% | 367,799 | -0.9% | 0.49% | +6.0% |
| Q3 2013 | $25,739,000 | +9.7% | 371,308 | +0.2% | 0.46% | +6.4% |
| Q2 2013 | $23,460,000 | +2.2% | 370,609 | +0.4% | 0.44% | -2.7% |
| Q1 2013 | $22,946,000 | – | 369,210 | – | 0.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |